Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) EBITDA Margin (2016 - 2025)

Sanara MedTech (SMTI) has disclosed EBITDA Margin for 15 consecutive years, with 18.66% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin fell 69.0% year-over-year to 18.66%, compared with a TTM value of 5.72% through Sep 2025, down 138.0%, and an annual FY2024 reading of 3.11%, up 291.0% over the prior year.
  • EBITDA Margin was 18.66% for Q3 2025 at Sanara MedTech, up from 10.32% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 19.34% in Q3 2024 and bottomed at 47.19% in Q4 2021.
  • Average EBITDA Margin over 5 years is 10.19%, with a median of 9.14% recorded in 2024.
  • The sharpest move saw EBITDA Margin crashed -2976bps in 2021, then skyrocketed 2750bps in 2022.
  • Year by year, EBITDA Margin stood at 47.19% in 2021, then skyrocketed by 58bps to 19.69% in 2022, then soared by 113bps to 2.54% in 2023, then crashed by -460bps to 9.14% in 2024, then soared by 304bps to 18.66% in 2025.
  • Business Quant data shows EBITDA Margin for SMTI at 18.66% in Q3 2025, 10.32% in Q2 2025, and 2.81% in Q1 2025.